Percutaneous Stellate Ganglion Block as First Line Treatment in Patients With Electrical Storm: the STAR 2 Study
A legfontosabb adatok
- Ki végzi
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Hol
- Olaszország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 3. fázis
- Résztvevők
- 180 fő, tervezett
- Kezdés
- 2026. okt. 1.
- Várható befejezés
- 2029. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- L-PSGB first
- A regiszteradat frissítve
- 2026. szeptember 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with electrical storm, meaning repeated fast dangerous heart rhythms (VT/VF) needing defibrillator treatment. It compares a stellate ganglion block (a numbing injection in the neck) with intravenous amiodarone as first treatment.
- Életkor
- 18 years and older
- Nem
- All sexes can join
- A betegség stádiuma
- More than 3 episodes of fast VT/VF treated by an internal or external defibrillator in the 12 hours before randomization, with at least one in the 3 hours before. People may have any structural heart disease, acute or chronic coronary disease, or CPVT.
- Korábbi kezelés
- People cannot join if they had a heart transplant, surgical sympathetic denervation or ablation of the stellate ganglion before. People currently on intravenous antiarrhythmic drugs usually cannot join.
A részvétel fő kizáró okai
- Brugada syndrome or early repolarization syndrome
- Neck judged not workable for the procedure, or cardiac arrest that does not respond to treatment
- Pregnancy or breastfeeding
- Allergy to amiodarone, lidocaine or bupivacaine, or reasons these drugs cannot be used (such as long QT, heart block without a pacemaker, active hyperthyroidism, severe low blood pressure)
- Investigational drug in another trial within 30 days of screening or within 5 half-lives, whichever is longer
A regiszter feltételei, szó szerint
Mind a 17 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- More than 3 episodes of fast-VT/VF treated by the internal or external defibrillator in the 12 hours before randomization and at least one in the three hours before
- Fast-VT or FV requiring internal or external treatment
- Any structural heart disease
- Acute or choric coronary disease
- CPVT
Ki nem vehet részt
- Previous heart transplantation
- Previous surgical sympathetic denervation
- Previous ablation of the stellate ganglion block
- Ongoing treatment with intravenous AAD drugs. Enrolment may be possible under certain circumstances (see Table 3 page 62-63) in case of recurrences after discontinuation
- Participation in a clinical trial in which an investigational drug was administered within 30 days of screening or within the 5 half-lives of the study drugs whichever is longer
- Known allergy or hypersensitivity or previous idiosyncrasy to amiodarone, lidocaine, bupivacaine or to any of the excipients
- Brugada syndrome or early repolarization syndrome
- Refractory cardiac arrest
- Contraindications to amiodarone or other study drugs (e.g. QT interval prolongation or known Long-QT syndrome, sick sinus syndrome, without a pacemaker; second- or third-degree AV block, without a pacemaker, active hyperthyroidism, severe hypotension, porphyria, untreated pheochromocytoma)
- Neck judged unfeasible for the procedure by the clinicians
- Pregnancy or breastfeeding
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Electrical storm (ES) is a life-threatening condition characterized by recurrent episodes of ventricular tachycardia (VT) or ventricular fibrillation (VF) requiring anti-tachycardia pacing or defibrillator shocks. Despite advances in management, ES remains associated with high morbidity and mortality, and current pharmacological options are often insufficient or slow-acting.
A teljes eredeti leírásKevesebb
The STAR 2 study is a multicentre, randomized, open-label, adaptive superiority trial designed to evaluate whether percutaneous stellate ganglion block (PSGB) as first-line therapy is superior to intravenous amiodarone in patients with ES. The primary hypothesis is that PSGB administered as initial treatment will result in a higher proportion of patients achieving complete suppression of treated ventricular arrhythmias during the first three hours after treatment compared with intravenous amiodarone.
Adult patients presenting with electrical storm, defined as three or more episodes of fast VT/VF (cycle length <400 ms) treated by internal or external defibrillator within the preceding 12 hours, including at least one episode in the three hours before randomization, will be eligible for participation. Patients will be randomly assigned in a 1:1 ratio to receive either PSGB or intravenous amiodarone as first-line treatment.
In the intervention arm, patients will undergo left PSGB using a combination of 200 mg lidocaine and 50 mg bupivacaine injected percutaneously at the level of the left stellate ganglion. The procedure may be repeated once within the first three hours in case of arrhythmic recurrence, without exceeding maximum recommended doses. In the control arm, patients will receive intravenous amiodarone according to a standardized protocol consisting of a 300-mg loading dose over 30 minutes followed by 900 mg infused over 18-24 hours.
The primary outcome is the proportion of patients with complete suppression of treated ventricular arrhythmias (defined as VT/VF episodes requiring anti-tachycardia pacing, internal cardioverter-defibrillator shock, or external defibrillator shock) during the first three hours after treatment administration. Secondary outcomes include time to first recurrence of ventricular arrhythmia within three hours, per-patient rate of treated ventricular arrhythmias in the first three and twelve hours after treatment, crossover rate between treatment arms, survival to hospital discharge, and survival at one month. Safety outcomes will include procedure- and drug-related complications and adverse events.
The study plans to enroll up to 180 patients across multiple centres. An adaptive design with pre-specified interim analyses for futility and efficacy will be employed, allowing for early termination if predefined statistical boundaries are crossed. Participants will be followed throughout hospitalization and for 30 days after discharge.
This trial aims to provide robust evidence on the comparative effectiveness and safety of PSGB versus standard antiarrhythmic therapy when used as first-line treatment in patients with electrical storm, potentially supporting a shift in current management strategies.
A vizsgálat 2 csoportja
- Amiodarone first (SoC)Nincs vizsgálati kezelés, összehasonlításként
Control group receiving intravenous amiodarone infusion as first-line treatment. According to guidelines Amiodarone is the most commonly used intravenous antiarrhythmic drug and represents the current standard of care.
- L-PSGB firstA vizsgált kezelés
Intervention group receiving left percutaneous stellate ganglion block (L-PSGB) as first-line treatment. The procedure consists of a single injection (bolus), at the level of the left-sided Chassaignac's tubercle (C6), of a combination of 200 mg lidocaine and 50 mg bupivacaine. Repetition of PSGB can be considered in case of arrhythmic recurrence within the first three hours.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Multicentre Randomised Study on Percutaneous Stellate Ganglion Block as First Line Treatment in Patients With Electrical Storm: the STAR 2 Study.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 29.